1. A machine
having a rotor which is mounted rotatably about an axis of rotation, and
a) has a rotor outer casing which is fixed to axial rotor shaft parts and surrounds a winding support having a superconductive winding, and
b) has means for holding the winding support within the rotor outer casing which comprise, on a torque-transmitting side, a first rigid connecting device between the winding, support and the rotor outer casing and, on the opposite side, a second connecting device, compensating for changes caused by the axial expansion of the winding support, and
having means for cooling and thermally insulating the superconductive winding,
characterized in that the second connecting device (8b), compensating for changes caused by expansion, has at least one axially extending connecting element (12) which is, on one side, rigidly connected to the winding support (9) and whose opposite, free end (12a) is connected to at least one centering holding element (18) of the rotor outer casing (7b) in an axially moveable and radially force-fitting manner.
2. The machine as claimed in claim 1, characterized in that the axially extending connecting element (12) is of a hollow-cylindrical design.
3. The machine as claimed in claim 1 or 2, characterized in that the axially extending connecting element (12), at its free end (12a), projects into an opening (20) in the holding element (18) such that it slides in a play-free manner.
4. The machine as claimed in claim 3, characterized in that the axially extending connecting element (12) is provided on its free end (12a) with a supporting ring (15) which projects into the opening (20) in the holding element (18).
5. The machine as claimed in one of the preceding claims, characterized in that the holding element (18) andor the free end (12a) of the connecting element (12) areis provided with radially extending extensions (17i), against which the free end (12a) of the connecting element (12) or the holding element (18) bears in the axial direction such that it slides in a play-free manner.
6. The machine as claimed in claim 5, characterized in that the extensions (17i) are of a protrusion- or tooth-shaped design.
7. The machine as claimed in one of the preceding claims, characterized in that the axially extending connecting element (12) is arranged centrally with respect to the rotor axis (A).
8. The machine as claimed in one of claims 1 to 6, characterized in that the second connecting device has a plurality of axially extending connecting elements arranged on an imaginary cylinder outer surface, the free ends of these connecting elements being connected to the at least one holding element in an axially moveable and radially force-fitting manner.
9. The machine as claimed in claim 8, characterized in that the connecting elements are of a bar- or rod-shaped design.
10. The machine as claimed in one of the preceding claims, characterized in that at least the axially extending connecting element (12) is made of a fiber-reinforced plastic material.
11. The machine as claimed in one of the preceding claims, characterized in that the conductors of the superconductive winding (10) contain a metallic low-Tc superconductor material or a metal-oxide high-Tc superconductor material.
12. The machine as claimed in one of the preceding claims, characterized in that a vacuum space is provided at least between the rotor outer casing (7) and the winding support (9).
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method for measuring a glycoprotein comprising:
contacting a sample collected from a subject with a lectin selected from WFA, BPL, AAL, RCA120, and TJAII; and
measuring Mac-2-binding protein (M2BP) binding to the lectin.
2. The method for measuring a glycoprotein according to claim 1, comprising measuring M2BP binding to a lectin for normalization of which reactivity is not substantially altered regardless of glycan structural changes in M2BP and normalizing the measured value of M2BP binding to the lectin using the measured value of M2BP binding to the lectin for normalization.
3. The method for measuring a glycoprotein according to claim 2, wherein the lectin for normalization is DSA.
4. The method for measuring a glycoprotein according to claim 1, wherein the contacting is performed by contacting the sample, the lectin and a labeled anti- M2BP antibody, and forming a complex of the lectin, the M2BP, and the labeled anti- M2BP antibody,
wherein the measuring is performed by measuring the amount of the label of the complex, and
quantitatively determining the M2BP binding to the lectin.
5. The method for measuring a glycoprotein according to claim 4, wherein the complex is formed using magnetic particles to which the lectin is immobilized.
6. The method for measuring a glycoprotein according to claim 4, wherein the complex is formed using the biotinylated lectin and magnetic particles to which streptavidin or avidin are immobilized.
7. The method for measuring a glycoprotein according to claim 4, wherein the label of the labeled anti-M2BP antibody is deglycosylated alkaline phosphatase.
8. The method for measuring a glycoprotein according to claim 4, wherein the anti-M2BP antibody is a deglycosylated anti-M2BP antibody.
9. The method for measuring a glycoprotein according to claim 1, wherein the measuring is performed by measuring M2BP binding to the lectin with the use of a lectin array to which at least the lectin is immobilized and an anti-M2BP antibody.
10. The method for measuring a glycoprotein according to claim 10, wherein:
DSA is further immobilized to the lectin array;
M2BP binding to DSA is measured and then the measured value of M2BP binding to the lectin is normalized using the measured value of M2BP binding to DSA.
11. A method for examining liver disease, whereby the stage of fiber formation in the liver is determined based on the measured value of M2BP obtained by the method for measuring M2BP according to claim 1.
12. A method for examining liver disease, whereby whether or not the disease is cirrhosis based on the measured value of M2BP obtained by the method for measuring M2BP according to claim 1.
13. A method for examining liver disease, whereby a risk of recurrence of hepatic cell carcinoma is determined based on the measured value of M2BP obtained by the method for measuring M2BP according to claim 1.
14. A method for determining the therapeutic effect of an anti-viral agent in treatment for liver disease, based on the measured value of M2BP obtained by the method for measuring M2BP according to claim 1.
15. A reagent for quantitative determination of a Mac-2-binding protein (M2BP), comprising magnetic particles to which a lectin selected from WFA, BPL, AAL, RCA120, and TJAII is immobilized and a labeled anti-M2BP antibody.
16. A glycan marker as an index for clinical conditions of liver disease, comprising a Mac-2-binding protein (M2BP) having liver-disease-specific glyco-alterations and binding to a lectin selected from WFA, BPL, AAL, RCA120, and TJAII.
17. A method for measuring a glycoprotein comprising:
contacting a sample collected from a subject with a lectin selected from AOL and MAL; and
measuring alpha-1-acid glycoprotein (AGP) binding to the lection.
18. The method for measuring a glycoprotein according to claim 17, comprising measuring AGP binding to a lectin for normalization of which reactivity is not substantially altered regardless of glycan structural changes in AGP and normalizing the measured value of AGP binding to the lectin using the measured value of AGP binding to the lectin for normalization.
19. The method for measuring a glycoprotein according to claim 18, wherein the lectin for normalization is DSA.
20. The method for measuring a glycoprotein according to claim 17 wherein the contacting is performed by contacting the sample, the lectin and a labeled anti- AGP antibody, and forming a complex of the lectin, the AGP, and the labeled anti- AGP antibody,
wherein the measuring is performed by measuring the amount of the label of the complex; and
quantitatively determining the AGP binding to the lectin.
21. The method for measuring a glycoprotein according to claim 20, wherein the complex is formed using magnetic particles to which the lectin is immobilized.
22. The method for measuring a glycoprotein according to claim 20, wherein the complex is formed using the biotinylated lectin and magnetic particles to which streptavidin or avidin are immobilized.
23. The method for measuring a glycoprotein according to claim 20, wherein the label of the labeled anti- AGP antibody is deglycosylated alkaline phosphatase.
24. The method for measuring a glycoprotein according to claim 20, wherein the anti- AGP antibody is a deglycosylated anti- AGP antibody.
25. The method for measuring a glycoprotein according to claim 20, wherein the measuring is performed by measuring AGP binding to the lectin with the use of a lectin array to which at least the lectin is immobilized and an anti- AGP antibody.
26. The method for measuring a glycoprotein according to claim 10, wherein:
DSA is further immobilized to the lectin array;
AGP binding to DSA is measured and then the measured value of AGP binding to the lectin is normalized using the measured value of AGP binding to DSA.
27. A method for examining liver disease, whereby the stage of fiber formation in the liver is determined based on the measured value of AGP obtained by the method for measuring AGP according to claim 17.
28. A method for examining liver disease, whereby whether or not the disease is cirrhosis based on the measured value of AGP obtained by the method for measuring AGP according to claim 17.
29. A method for examining liver disease, whereby a risk of recurrence of hepatic cell carcinoma is determined based on the measured value of AGP obtained by the method for measuring AGP according to claim 17.
30. A method for determining the therapeutic effect of an anti-viral agent in treatment for liver disease, based on the measured value of AGP obtained by the method for measuring AGP according to claim 17.